Oncogenic Mutations and Gene Fusions in CD30-Positive Lymphoproliferations and Clonally Related Mycosis Fungoides Occurring in the Same Patients

Marion Wobser1,2,3, Sabine Roth3,4, Silke Appenzeller3, Hermann Kneitz1,2,3, Matthias Goebeler1,2,3, Eva Geissinger5, Andreas Rosenwald3,4 and Katja Maurus3,4

The emergence of a common progenitor cell has been postulated for the association of CD30-positive lymphoproliferative disease (LPD) and mycosis fungoides (MF) within the same patient. Up to now, no comprehensive analysis has yet addressed the genetic profiles of such concurrent lymphoma subtypes. We aimed to delineate the molecular alterations of clonally related CD30-positive LPD and MF occurring in the same two patients. We analyzed the molecular profile of 16 samples of two patients suffering both from CD30-positive LPD and MF being obtained over a time course of at least 5 years. To detect oncogenic mutations, we applied targeted sequencing technologies with a hybrid capture-based DNA library preparation approach, and for the identification of fusion transcripts, an anchored multiplex PCR enrichment kit was used. In all samples of CD30-positive LPD and MF, oncogenic fusions afflicting the Jak/signal transducer and activator of transcription signaling pathway were present, namely NPM1–TYK2 in patient 1 and ILF3–JAK2 in patient 2. Additional signal transducer and activator of transcription 5A gene STAT5A mutations exclusively occurred in lesions of CD30-positive LPD in one patient. CD30-positive LPD and MF may share genetic events when occurring within the same patients. Constitutive activation of the Jak/signal transducer and activator of transcription signaling pathway may play a central role in the molecular pathogenesis of both entities.

INTRODUCTION

During the last decade, a significant progress has been achieved to decipher the molecular pathogenesis of cutaneous lymphomas (Chevret and Merlio, 2016; da Silva Almeida et al., 2015; Damsky and Choi, 2016; McGirt et al., 2015; Prasad et al., 2016; Ungewickell et al., 2015; Wang et al., 2015; Woollard et al., 2016). Shared molecular profiles with convergent genetic aberrations in pivotal oncogenic pathways could be identified in mycosis fungoides (MF) or Sézary syndrome (Bastidas Torres et al., 2018b; Chang et al., 2018). Increasing insight into key genetic drivers does not only help to better understand the pathogenesis of cutaneous lymphomas but also opens the field for better prognostic algorithms and paves the way for the development of novel patient-specific targeted treatment options.

Until recently, only limited data had been available on the molecular pathogenesis and the key drivers of cutaneous CD30-positive lymphoproliferative diseases (LPDs) (Karai et al., 2013). The spectrum of these disorders includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphomas (cALCLs) (Bennner and Willemze, 2009). As a unifying oncogenic mechanism in both entities, rearrangements involving the DUSP22/IRF4 locus have been identified in 5% of LyP (Karai et al., 2013) and in up to 30% of cALCL (Feldman et al., 2009; Wada et al., 2011). Moreover, similar DUSP22 rearrangements were also detected in 18% of CD30-positive transformed MF (Pham-Ledard et al., 2010). We recently deciphered further common molecular mechanisms of transformation occurring in up to 50% of CD30-positive LPDs by detecting highly recurrent activating hotspot mutations and oncogenic fusion transcripts that directly affect the Jak and signal transducer and activator of transcription (STAT) signaling pathway (Maurus et al., 2020). Motivated by these findings, we analyzed the molecular profile with respect to TCR rearrangement, oncogenic mutations, as well as gene fusions in two patients who each presented with concomitant or sequentially occurring distinct lesions of both CD30-positive LPD as well as MF. During a disease course of at least 5 years and a remarkably long follow-up of over 10 years in total, we were able to include

1Department of Dermatology, Venerology and Allergology, University Hospital Würzburg, Würzburg, Germany; 2Skin Cancer Center, Oncology Center Würzburg (OZW), Comprehensive Cancer Center Mainfranken (CCC Mainfranken), University Hospital Würzburg, Würzburg, Germany; 3Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany; 4Institute of Pathology, Faculty of Medicine, University of Würzburg, Würzburg, Germany; and 5Pathology Practice, Ingolstadt, Germany

Correspondence: Marion Wobser, Department of Dermatology, Venerology and Allergology, University Hospital Würzburg, Josef-Schneider-Street 2, 97080 Würzburg, Germany. E-mail: wobser_m@ukw.de

Abbreviations: cALCL, cutaneous anaplastic large cell lymphoma; LPD, lymphoproliferative disease; LyP, lymphomatoid papulosis; MF, mycosis fungoides; PMID, PubMed ID; STAT, signal transducer and activator of transcription

Received 21 December 2020; revised 13 April 2021; accepted 14 April 2021; accepted manuscript published online 15 June 2021; corrected proof published online 7 August 2021

Cite this article as: JID Innovations 2021;1:100034

© 2021 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). www.jidinnovations.org
sequentially obtained biopsy samples (n = 16) of these two patients into our genetic analysis with a corresponding well-documented clinicopathological correlation of each assessed lesion.

RESULTS
To decipher the molecular characteristics of CD30-positive LPDs linked to MF, we performed different genetic screening analyses of 16 samples of two well-characterized patients (Figure 1 and Table 1).

Both patients suffer from MF and CD30-positive LPD
Patient 1 presented at the time of the first diagnosis with a long-standing MF stage IB with patches and plaques. He additionally developed at different time points during the further clinical course (total follow-up since the date of the first diagnosis is 41 years) small regressing papules being diagnosed as LyP. Whereas all MF samples were CD30 negative on histology with small epidermotropic CD4-positive lymphocytes as per definition, the LyP lesions showed strong expression of CD30 by the large neoplastic blasts (LyP type A). Close clinicopathological correlation yielded a clear-cut diagnosis for each lesion of patient 1 with an unequivocal attribution to the respective lymphoma subtypes (Figure 2). Samples for this analysis (n = 8) were obtained during a time course of 7 years (2012–2019).

Patient 2 was initially diagnosed with small-cell CD30-negative CD4-positive MF in stage IA. During the further disease course, the patient developed papules being compatible with LyP. Whereas all MF samples were CD30 negative on histology with small epidermotropic CD4-positive lymphocytes as per definition, the LyP lesions showed strong expression of CD30 by the large neoplastic blasts (LyP type A). Close clinicopathological correlation yielded a clear-cut diagnosis for each lesion of patient 1 with an unequivocal attribution to the respective lymphoma subtypes (Figure 2). Samples for this analysis (n = 8) were obtained during a time course of 7 years (2012–2019).

Patient 2 was initially diagnosed with small-cell CD30-negative CD4-positive MF in stage IA. During the further disease course, the patient developed papules being compatible with LyP. In this patient, two lesions (samples 10 and 15) had to be designated as quite ambiguous or borderline on histological and/or clinical grounds. First, one larger papular lesion in patient 2 (sample 10) had been completely excised shortly after the occurrence, and therefore, no data on potential self-healing tendency could be obtained. This lesion was hence classified somehow with caution as LyP type C taking into account the possible differential diagnosis of transformed CD30-positive MF or cALCL, especially with regard to sheet-like CD30-positive atypical blasts in the dermis and the further disease course exhibiting quite extensive involvement of a draining lymph node. Secondly, one biopsy of an ulcerated small plaque (sample 15) in close proximity to spontaneously regressing

Table 1. Patient Characteristics

| Patient Characteristics | Patient 1 | Patient 2 |
|-------------------------|-----------|-----------|
| Sex                     | M         | F         |
| Year of birth           | 1944      | 1939      |
| Age at diagnosis, y     | 35        | 67        |
| Date of primary diagnosis | 1979    | 2006      |
| Lymphoma subtype at primary diagnosis | MF stage IB | MF stage IA |
| Date of the first occurrence of LyP lesions | 2002 | 2018 |
| Sequential treatment    | Topical steroids, PUVA, IFN, bexarotene, MTX | Topical steroids, PUVA, bexarotene, MTX, local irradiation, brentuximab |
| Current treatment       | Topical steroids | Brentuximab |
| Extracutaneous manifestations | No        | Yes (inguinal lymph node) |
| Follow-up, y            | 41        | 14        |
| Final status            | Alive with lymphoma (MF with patches/plaques <10% BSA) | Alive with lymphoma (MF with patches/plaques <10% BSA) |

Abbreviations: BSA, body surface area; F, female; LyP, lymphomatoid papulosis; M, male; MF, mycosis fungoides; MTX, methotrexate; PUVA, psoralen plus UVA.

Figure 1. Representative clinical images of patients 1 and 2. (a–c) Patient 1. (a) Localized patches histologically proven as MF at the back, buttocks, and both thighs (date of presentation: 2012). (b) Slowly progressive patches of MF (date of presentation: 2017) with agminated self-healing papules corresponding to LyP lesions. Close-up view of the indicated cut-out in c. (d–f) Patient 2. (d) Disseminated long-standing patches and (e) spontaneously regressing papules at the trunk and extremities (date of presentation: 2019). Close-up view of the indicated cut-out in f. Patients consented to the publication of their images. LyP, lymphomatoid papulosis; MF, mycosis fungoides.
classical LyP papules exhibited on histology small epidermotropic lymphocytes with a faint expression of CD30 in about 20% of lymphoma cells. For this lesion, diagnosis of partially CD30-positive MF was favored over a possible differential diagnosis of LyP type D. However, all other lesions were clearly attributable to either MF or CD30-positive LPD (Figure 2). The analyzed lesions (n = 8) of patient 2 were obtained during a time course of 5 years (2015–2020).

Figure 2. Representative clinical and histological images for each biopsy. Clinical features, area of biopsy taken for routine histology (FFPE), and photomicrographs of corresponding histological sections (H&E staining, CD30 staining) are illustrated for each patient over the disease course. Lesions of MF (patches, plaques) with no or faint/low CD30 expression of small neoplastic lymphocytes are indicated by an asterisk. All skin lesions with papular/nodular morphology and all lesions with large CD30-positive blasts on histology are indicated by a red arrow. Strong CD30 expression was found with variable frequency depending on LyP subtype (A vs. C). The lymph node showed focal nodular, sheet-like CD30-positive lymphoma infiltration rather than diffusely scattered lymphoma cells. Patients consented to the publication of their images. cALCL, cutaneous anaplastic large cell lymphoma; DD, differential diagnosis; FFPE, formalin-fixed, paraffin-embedded; LyP, lymphomatoid papulosis; MF, mycosis fungoides; NA, not available; tMF, transformed mycosis fungoides.
Clonality analysis displays cognitional monoclonal T-cell populations in MF and CD30-positive LPD within the same patient
Concordant monoclonal amplificates were detected in each patient across all lymphoma subtypes (Table 2). These findings imply the close clonal relationship between MF and CD30-positive LPD within each of the two investigated patients.

RNA panel sequencing reveals oncogenic Jak fusions, including TYK2 and JAK2
To determine pathogenic fusion transcripts, several samples of both patients were screened with Archer FusionPlex Pan-Heme panel (ArcherDX, Boulder, CO) comprising 199 genes being implicated in lymphomagenesis. In both examined patients, Jak fusions were detected (Table 2).
Patient 1 showed an NPM1–TYK2 (breakpoints according to hg19: chr5:170827929 and chr19:10468814) fusion transcript in the sequenced samples of both MF and CD30-positive LPD. To verify the presence of this oncogenic transcript in all tissue samples across all entities of patient 1, confirmatory PCR detection for the NPM1–TYK2 transcript was conducted. All evaluated samples were positive for this transcript.

Patient 2 showed a different Jak fusion transcript, namely ILF3–JAK2 (breakpoints according to hg19: chr19:10794646 and chr9:5080229) in the analyzable sequenced samples (9, 13, and 14). Samples 10—12 and 16 failed owing to low RNA quality extracted from archived formalin-fixed paraffin-embedded material. Confirmatory ILF3–JAK2 PCR analyses affirmed the presence of this fusion transcript in all assessable lesions of both CD30-positive LPD and MF.

No DUSP22 rearrangements (investigated by FISH analysis) or ALK fusions/expression were detected in any samples obtained from the two patients.
Targeted DNA panel sequencing shows STAT5A mutations in CD30-positive LPD but not in CD30-negative MF of the same patient

After having detected the unifying genetic events in lesions of CD30-positive LPD and MF within these two patients, that is, shared T-cell clonality and oncogenic gene fusions afflicting the Jak gene, we further scrutinized the samples by deep sequencing. Our aim was to identify further molecular aberrations that could differentiate LyP from MF and thus may explain the distinct biological behavior and different histological and clinical phenotypes of these specific lymphoma subtypes.

We used a custom-designed DNA panel comprising 40 genes that are associated with T- and B-cell development and
lymphomagenesis as described elsewhere (Maurus et al., 2020). An overview of all detected mutations is shown in Table 2. No relevant germline mutations were identified.

In patient 1, we detected in all investigated samples of LyP (samples 1, 4, and 7) an identical STAT5A mutation (c.1297G > A, p.E433K, NM_003152.3). This hitherto unreported STAT5A mutation is located within the DNA-binding domain of the STAT5A protein, thus probably harboring the potential to activate the Jak/STAT signaling pathway. Of note, these STAT5A mutations were not present in any of the analyzed/evaluable MF lesions of patient 1. Hence, the exclusive presence of STAT5A mutations in CD30-positive LPD lesions but not in MF lesions within this same patient represents the cardinal discriminatory molecular feature in our applied genetic approach between these two lymphoma subtypes. For all other genes included in the panel, we obtained wild-type sequences for both lymphoma entities in patient 1.

In all evaluable samples (n = 6) of patient 2, the same oncogenic DNMT3A mutation (c.2186G > A, p.R729Q, NM_02255.4) could be detected in addition to the shared ILF3–JAK2 fusion mentioned earlier. This DNMT3A mutation is predicted to be pathogenic and has already been described in other hematologic neoplasms (Ley et al., 2010). The
| Sample | Date of Biopsy | Lesion Type | Diagnosis | Large Cell Morphology | CD30 Positivity > 10% | Gene | Mutation (cDNA) | Mutation (Protein) | Fusions | DUSP22 | Clonality (TCRG) |
|--------|----------------|-------------|-----------|-----------------------|-----------------------|------|----------------|-------------------|---------|--------|------------------|
| 1      | 2012           | Papule      | LyP       | Yes                   | Yes                   | STAT5A | c.1297G > A   | p.E433K           | NPM1--TYK2 | Neg    | Monoclonal 220 bp |
| 2      | 2012           | Patch       | MF        | No                    | No                    | STAT5A | c.1297G > A   | p.E433K           | NPM1--TYK2 | Neg    | Monoclonal 220 bp |
| 3      | 2014           | Plaque      | MF        | No                    | No                    | STAT5A | c.1297G > A   | p.E433K           | NPM1--TYK2 | Neg    | Monoclonal 220 bp |
| 4      | 2017           | Papule      | LyP       | Yes                   | Yes                   | STAT5A | c.1297G > A   | p.E433K           | NPM1--TYK2 | Neg    | Monoclonal 220 bp |
| 5      | 2017           | Patch       | MF        | No                    | No                    | STAT5A | c.1297G > A   | p.E433K           | NPM1--TYK2 | Neg    | Failed           |
| 6      | 2019           | Plaque      | MF        | No                    | No                    | STAT5A | c.1297G > A   | p.E433K           | NPM1--TYK2 | Neg    | Failed           |
| 7      | 2019           | Papule      | LyP       | Yes                   | Yes                   | STAT5A | c.1297G > A   | p.E433K           | NPM1--TYK2 | Neg    | Monoclonal 220 bp |
| 8      | 2019           | Patch       | MF        | No                    | No                    | STAT5A | c.1297G > A   | p.E433K           | NPM1--TYK2 | Neg    | Monoclonal 220 bp |
| 9      | 2015           | Infiltrated plaque | MF | No                    | No                    | PLCG1  | c.1034C > T   | p.S345F subclonal 2% | ILF3--JAK2 | NA    | Monoclonal 162 bp |
| 10     | 2018           | Large papule | LyP, DD cALCL, tMF | Yes       | Yes                   | PLCG1  | c.1034C > T   | p.S345F subclonal 2% | ILF3--JAK2 | NA    | Monoclonal 162 bp |
| 11     | 2018           | Patch       | MF        | No                    | No                    | PLCG1  | c.1034C > T   | p.S345F subclonal 2% | ILF3--JAK2 | NA    | Monoclonal 162 bp |
| 12     | 2018           | Patch       | MF        | No                    | No                    | PLCG1  | c.1034C > T   | p.S345F subclonal 2% | ILF3--JAK2 | NA    | Monoclonal 162 bp |
| 13     | 2019           | Papule      | LyP       | Yes                   | Yes                   | PLCG1  | c.12254C > G  | p.L752V           | ILF3--JAK2 | Neg    | Monoclonal 162 bp |
| 14     | 2019           | Plaque      | MF        | No                    | No                    | PLCG1  | c.12254C > G  | p.L752V           | ILF3--JAK2 | Neg    | Monoclonal 162 bp |
| 15     | 2019           | Ulcerated plaque | MF | No                    | Yes (faint)           | PLCG1  | c.12254C > G  | p.L752V           | ILF3--JAK2 | Neg    | Monoclonal 162 bp |
| 16     | 2020           | Lymph node  | LyP, DD cALCL, tMF | Yes       | Yes                   | PLCG1  | c.12254C > G  | p.L752V           | ILF3--JAK2 | NA    | Monoclonal 162 bp |

Abbreviations: cALCL, cutaneous anaplastic large T-cell lymphoma; DD, differential diagnosis; FFPE, formalin-fixed paraffin-embedded; LyP, lymphomatoid papulosis; NA, not available; Neg, negative; tMF, transformed mycosis fungoides; wt, wild type.

Failed implied that the analysis failed owing to limited DNA and RNA quality from archived FFPE material.
presence of DNMT3A mutations was irrespective of lymphoma subtype and corresponding phenotype (large cell morphology, CD30-expression).

Albeit with a lower frequency, also PLCG1 mutations (c.1034C > T, p.S345F and c.2254C > G, p.L752V) could be detected in patient 2. To our astonishment, these PLCG1 mutations were present both in samples obtained from the lesions of CD30-positive LPD (n = 1) and those obtained from CD30-negative MF (n = 2) (sample 9: c.1034C > T, p.S345F; sample 13, 14: c.2254C > G, p.L752V, NM_002660.3). The oncogenic PLCG1 p.S345F mutation has already been described in MF, has been functionally analyzed, and thus was designated as pathogenetically relevant (Vaque et al., 2014). The second PLCG1 mutation detected in our study (PLCG1 p.L752V) lacks till now any entry in relevant databases and is devoid of further functional characterization. However, a different mutation (PLCG1 p.L752Q) that affects the same codon as PLCG1 p.L752V has been predicted to be pathogenic according to the cosmic database. This fact suggests a potential relevance/pathogenicity of the variant (p.L752V) in the samples of patient 2 detected in this study. With respect to the two different lymphoma subtypes in this patient, we could not identify any mutation being exclusively present in only one versus the other lymphoma subtype as was the case in patient 1.

DISCUSSION

The concomitant or sequential association of LyP with additional solid or hematologic tumors—mainly cutaneous lymphomas (MF, cALCL) as in our two patients—has been known for decades and has been recently reassured by three larger retrospective studies (Cordel et al., 2016; Melchers et al., 2020a, 2020b, 2020c). Nevertheless, these lymphoma subtypes are rare disease entities, especially when occurring in combination within the same patient, and research data beyond clinical registries are mainly limited to case reports or small case series.

Owing to overlapping T-cell clones in lesions of LyP, cALCL, and/or MF within the same patient, the origin of a common progenitor cell has already been postulated before. Molecular workup of such cases was hitherto merely limited to PCR analysis of the TCR gene (Basarab et al., 1998; de la Garza Bravo et al., 2015; Stowman et al., 2016; Zackheim et al., 2003). Being in line with these previous publications, in our patients, an identical T-cell clone could be identified in all evaluable samples of the skin and lymph nodes in each of the two patients, respectively.

The first study published last year taking advantage of a more sophisticated approach recently addressed this issue by means of targeted next-generation sequencing and comparative genomic hybridization of samples taken from clonally related lesions of LyP and cALCL in one single patient (Xerri et al., 2019). However, in this specific case, despite a shared T-cell clone, rather distinct genetic profiles were described in each of these two entities (Xerri et al., 2019). This implies early divergence of respective subtypes from a common precursor cell in this patient. However, the presence of gene fusions—as addressed by our approach—was not the scope of this previous analysis.

By our meticulous genetic analysis of sequential biopsies (n = 16) of two different patients, we could observe several shared molecular aberrations comprising fusions and mutations in lesions of CD30-positive LPD and MF. Moreover, the pattern of the detected genetic events remained quite stable over time and was conserved in lesions occurring later on during clinical course over a follow-up of >5 years. Hence, divergent from the report mentioned earlier (Xerri et al., 2019), our findings suggest a rather late divergence of a common progenitor cell retaining its genetic profile even over decades. This was especially true for the detected gene fusions NPM1–TYK2 and ILF3–JAK2, which were invariably present in all evaluable samples of each patient, respectively.

The identified fusion transcripts follow a classical mechanism of genomic translocations by fusing (i) effector domains of oncogenic driver genes with (ii) ubiquitously and strongly expressed genes of central cellular processes. In this case, we found the functionally relevant kinase domains of Jak (JAK2 and TYK2) being fused to widely expressed RNA-binding proteins, namely the already described NPM1 gene (Velusamy et al., 2014) and ILF3. This mechanism ensures the constitutive expression of the Jak effector domains exhibiting their oncogenic downstream signaling characteristics. Thus, these fusions are likely to represent an early common molecular event for lymphomagenesis of both lymphoma entities and thus might represent possible therapeutic targets, for example, by applying Jak inhibitors.

In patient 1, the cardinal unifying genetic aberration was an NPM1–TYK2 fusion both in samples of LyP and MF mirroring this feature as the basic transforming mechanism for both lymphoma entities. Whereas NPM1–TYK2 fusions have already been described in CD30-positive LPD, up till now, no similar gene fusions had been described in MF or Sézary syndrome. In MF, a rather complex and heterogeneous landscape of interchromosomal and intrachromosomal rearrangements has been observed. Various translocations resulting in deletion of tumor suppressors such as SOCS1 or HNRNPK have recently been described in MF, which also mediate enhanced Jak signaling (Bastidas Torres et al., 2018a).

Of note, in patient 1, the LyP lesions could be unequivocally differentiated from MF lesions by clinical and histological/immunophenotypical findings and as well by discriminatory genetic features: additional STAT5A mutations were invariably present only in samples of LyP but not in samples of clonally related MF. Such a co-occurrence of fusions as well as mutations within the same pathway is a quite remarkable phenomenon. The detected STAT5A mutation (p.E433K) is located within the DNA-binding domain of the STAT5A protein with a proposed capacity to activate the Jak–STAT signaling pathway. This obvious molecular black-and-white pattern allows us to hypothesize that an aberrantly activated Jak–STAT pathway on the ground of a molecular two-hit-mechanism—oncogenic fusions followed by additional somatic mutations—may drive a common progenitor cell of patient 1 to a neoplastic lymphoma cell of LyP with consecutive distinct biological, histological, and clinical features.

Similar to patient 1, analogous rearrangements of genes of the Jak/STAT family, namely ILF3–JAK2 fusions, were also observed in evaluable lesions of patient 2. In addition, all evaluable lesions of both CD30-positive LPD and MF of
patient 2 exhibited the same DNMT3A mutation (p.R729V) being predicted to impair the catalytic methyltransferase activity. As far as we know, alterations of the DNMT3A gene have not been described in LyP or cALCL. In contrast, recurrent alterations of epigenetic regulators, including the DNMT3A gene (mutations, deletions), have been identified with variable frequencies in systemic anaplastic large cell lymphoma (Di Napoli et al., 2018), MF, peripheral T-cell lymphomas, and myeloid neoplasms (Chang et al., 2018; Choi et al., 2015; Damsky and Choi, 2016; Palomero et al., 2014) with prognostic and therapeutic implications (Ley et al., 2010; Park et al., 2020).

In contrast to universally present DNMT3A mutations in all samples, only 50% of the analyzed samples of patient 2 also showed PLCG1 mutations. Of note, these additional single nucleotide variants occurred irrespective of lymphoma subtype or phenotype. Moreover, no further mutations of Jak–STAT–related genes were present in samples obtained from this patient. Corresponding to these molecular data, differentiation between LyP and MF in patient 2 was not as clear cut as in patient 1: clinical, histological, and immunophenotypic findings suggested, for example, for samples 10 and 15 rather a continuum of these lymphoma subtypes with categorization as borderline as already discussed in the literature (Bekkenk et al., 2000; Fauconneau et al., 2015; Gao et al., 2021; Kadim et al., 2014). Until now, no reliable immunohistochemical or molecular marker has been established for daily routine to clearly differentiate CD30-positive MF from CD30-positive LPD. Hence, final diagnosis still relies on close clinicopathological correlation and meticulous monitoring of these patients (Bekkenk et al., 2000; Eberle et al., 2012; Fauconneau et al., 2013; Kadim et al., 2014; Kempf et al., 2011; Lezama and Gratzinger, 2018; Pham-Ledard et al., 2010; Vergier et al., 2000) as outlined in Figure 2.

Interestingly, the activating PLCG1 S345F mutation occurred subclonally in sample 9 but was not detectable anymore in later biopsies. Instead, the patient acquired an alternative PLCG1 mutation (p.L752V) in lymphoma lesions evolving during the further clinical course (13 and 14), thus underlining the general importance of PLCG1 alterations for lymphomagenesis. Single nucleotide variants in PLCG1 leading to constitutive activation of the nuclear factor of activated T-cells pathway have been designated as indicators of constitutive activation of the nuclear factor of activated T-cells pathway have been designated as indicators of pro-inflammatoryity. As far as we know, alterations of the PLCG1 gene (mutations, deletions) have not been described in LyP or cALCL. In contrast, recurrent alterations of epigenetic regulators, including the DNMT3A gene (mutations, deletions), have been identified with variable frequencies in systemic anaplastic large cell lymphoma (Di Napoli et al., 2018), MF, peripheral T-cell lymphomas, and myeloid neoplasms (Chang et al., 2018; Choi et al., 2015; Damsky and Choi, 2016; Palomero et al., 2014) with prognostic and therapeutic implications (Ley et al., 2010; Park et al., 2020).

In conclusion, CD30-positive LPD and MF harbor unifying molecular aberrations (Kempf et al., 2011; Willemze and Meijer, 2003). Our data on two patients presented in this paper further substantiate the concept that oncogenic fusions together with somatic mutations in JAK/STAT genes play a key role in the pathogenesis of CD30-positive LPD. Additional underlying molecular and epigenetic mechanisms that drive the final phenotype of the common precursor cell to evolve into skin manifestations corresponding to either LyP, cALCL, or MF still remain to be elucidated and will be the scope of further investigation.
Somatic variant calling. MuTect1, version 1.1.4 (PMID: 23396013); VarScan2, version 2.4.1 (PMID: 22300766); and Scalpel, version 0.5.3 (PMID: 27854363), were used to identify somatic single nucleotide variants and small somatic insertions or deletions (Supplementary Table S2). All variants were annotated with ANNOVAR, version 2019-10-24 (PMID: 20601685). Variants were considered somatic if they have an impact on the protein sequence or if they affect a splice site, if they are rare in the population (below a frequency of 2% in 1000g2015aug_all, ExAC_noncga_ALL, gnomAD_exome_ALL, and gnomAD_genome_ALL), if the position is covered by at least 20 reads and the alternative allele is covered by at least 8 reads, and if they comprised at least 2% and are absent in the matched normal blood sample.

All variants were visually examined using the Integrative Genomics Viewer, version 2.3.68 (Thorvaldsdóttir et al., 2013). In addition, all detected variants were checked in all corresponding samples of the same patient.

RNA fusion sequencing
We used an anchored multiplex PCR-based next-generation sequencing assay, including 199 genes related to lymphoid and myeloid malignancies, which allowed us to identify any fusion affecting these genes. RNA libraries were prepared of the following material: patient 1 samples 1, 3, and 4 and patient 2 samples 9–14 using the Archer FusionPlex Pan-Heme Kit strongly according to the Archer FusionPlex Protocol for Illumina. Libraries were sequenced on the NextSeq 500 platform (Illumina, San Diego, CA). Sequencing data were analyzed with the Archer Analysis software, version 6.2.3, using default parameters for quality assessment and fusion calling/annotation. Failed samples are mentioned in Table 2 and Figure 3 and were excluded from interpretation. In addition, to the Archer analysis pipeline, data were analyzed with an alternative tool. Therefore, adapters and low-quality reads were trimmed with TrimGalore, version 0.4.0, powered by Cutadapt, version 1.8. For fusion detection, Arriba, version 1.1.0, (https://github.com/suhrig/arriba), which is based on the STAR aligner, version 2.5.4b (https://github.com/alexdobin/STAR), was used with default settings. Strong fusions were considered for confirmatory PCR analyses.

PCR fusion analysis
The fusion target regions detected by targeted RNA sequencing were amplified from cDNA of all analyzed patient samples using DreamTaq-DNA Polymerase (Invitrogen, Carlsbad, CA). In addition, a GAPDH amplificate was generated to check for RNA/cDNA quality.

For the amplification of the NPM1–TYK2 and the ILF3–JAK2 fusions, the following primers were used:

- ACTCCAGCCAAAATGCACAAA (forward) and CTCAGCTTGAT-GAGGGGCT (reverse) for NPM1–TYK2 (59 °C annealing temperature, amplificate length 75 bp), GCTATGTTGACCCAGGACAC (forward) and TCAGGTGGATCCATGTTATC (reverse) for ILF3–JAK2 (60 °C annealing temperature, amplificate length 73 bp), and CCGCATCTCTTTCCTG (forward) and ATCCGGTACCTCC-GACCTTC (reverse) for GAPDH (60 °C annealing temperature, amplificate length 78 bp). Amplificates were separated on a 2% agarose gel (Figure 3).

DUSP22/IRF4 FISH screening
Paraffin sections were treated with the VP2000 processor (Abbott, Chicago, IL) and stained with the Kreatech IRF4/DUSP22 (6p25) Break FISH probe (Leica Biosystems, Wetzlar, Germany) for 16 hours at 37 °C. Stained slides were analyzed by fluorescent microscopy.

TCRG rearrangement analysis
T-cell clonality was analyzed by PCR amplification using the Biomed-2 primers for TCRG (van Dongen et al., 2003).

Data availability statement
Data sets related to this article can be found at https://www.ebi.ac.uk/ega/datasets, hosted at the European Genome-Phenome Archive (EGAS00001005094).

ORCIDs
Marion Wobser: http://orcid.org/0000-0002-6293-2554
Sabine Roth: http://orcid.org/0000-0002-4288-4751
Silke Appenzeller: http://orcid.org/0000-0002-5472-8692
Hermann Kneitz: http://orcid.org/0000-0002-9138-4550
Mathias Goebeler: http://orcid.org/0000-0001-7095-9848
Eva Geissinger: http://orcid.org/0000-0002-0966-0747
Andreas Rosenwald: http://orcid.org/0000-0001-7382-8374
Katja Maurus: http://orcid.org/0000-0002-3093-3114

AUTHOR CONTRIBUTIONS
Conceptualization: MW, KM; Data Curation: MW, SR, SA, HK, MG, EG, AR, KM; Formal Analysis: MW, KM, SA; Funding Acquisition: MW, KM, MG, AR; Investigation: MW, SR, SA, HK, MG, EG, AR, KM; Methodology: MW, SR, SA, KM; Writing: MW, KM

ACKNOWLEDGMENTS
We thank our patients for giving their consent to participate in our study. The patients in this manuscript have given written informed consent to the publication of their case details. Moreover, we are thankful to all those people being involved in further diagnostic and therapeutic management of the patients.
CONFLICT OF INTEREST
The authors state no conflict of interest.

SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper at www.jidonline.org, and at https://doi.org/10.1016/j.jid.2021.100034.

REFERENCES
Basarab T, Fraser-Andrews EA, Orchard G, Whittaker S, Russel-Jones R. Lymphomatoid papulosis in association with mycosis fungoides: a study of 15 cases. Br J Dermatol 1998;139:630–6.
Bastidas Torres AN, Cats D, Mei H, Szhuki K, Willemze R, Vermeer MH, et al. Genomic analysis reveals recurrent deletion of JAK-STAT signaling inhibitors HRNRNPK and SOCS1 in mycosis fungoides. Genes Chromosomes Cancer 2011;57:63–64.
Bastidas Torres AN, Najidh S, Tensen CP, Vermeer MH. Molecular advances in cutaneous T-cell lymphoma. Semin Cutan Med Surg 2018;37:81–6.
Bekkenk MW, Geelen FA, van Voorst Vader PC, Heule F, Geerts ML, van Vloten WA, et al. Primary and secondary cutaneous CD30(+)-lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000;95:3653–61.
Benner MF, Willemze R. Applicability and prognostic value of the new TNM classification system in 135 patients with primary cutaneous anaplastic large cell lymphoma. Arch Dermatol 2009;145:393–404.
Chang LW, Patrone CC, Yang W, Rabionet R, Gallardo F, Espinet B, et al. An integrated data resource for genomic analysis of cutaneous T-cell lymphoma. J Invest Dermatol 2018;138:2681–3.
Chevret E, Merlio JP. Sézary syndrome: translating genetic diversity into personalized medicine. J Invest Dermatol 2016;136:1319–24.
Choi J, Goh G, Walradt T, Hong BS, Bunick CG, Chen K, et al. Genomic landscape of cutaneous T cell lymphoma. Nat Genet 2015;47:1011–9.
Cordel N, Tressières B, D’Incan M, Machet L, Grange F, Estève E, et al. Frequency and risk factors for associated lymphomas in patients with lymphomatoid papulosis. Oncologist 2016;21:76–83.
da Silva Almeida AC, Abate F, Khiabian H, Martinez-Escalas E, Guitart J, Tensen CP, et al. The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome. Nat Genet 2015;47:1465–70.
Damske WY, Choi J. Genetics of cutaneous T-cell lymphoma: from bench to bedside. Curr Treat Options Oncol 2016;17:33.
de la Garza Bravo MM, Patel KP, Loghavi S, Curry JL, Torres Cabala CA, Cason RC, et al. Shared clonality in distinctive lesions of lymphomatoid papulosis and mycosis fungoides occurring in the same patients suggests a common origin. Hum Pathol 2015;46:558–69.
Di Napoli A, Jain P, Duranti E, Margolles E, Arancio W, Facchetti F, et al. Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A. Br J Haematol 2018;180:741–4.
Dippel E, Assaf C, Becker JC, von Bergwalt-Baldon M, Beyer M, Cozzio A, et al. S2k guidelines - cutaneous lymphomas update 2016 - part 1: classification and diagnosis (ICD10 C02 - C06). J Disch Dermatol Ges 2017;15:1266–73.
Eberle FC, Song JY, Xi L, Ralfeld M, Harris NL, Wilson WH, et al. Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma. Am J Surg Pathol 2012;36:716–25.
Faucanonne A, Pham-Ledard A, Cappellen D, Frison E, Prochazkova-Carlotti M, Parrens M, et al. Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases. Br J Dermatol 2015;172:1547–54.
Feldman AL, Law M, Remstein ED, Macon WR, Erickson LA, Grogg KL, et al. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia 2009;23:574–80.
Gao C, McCormack CJ, van der Weyden C, Twigger R, Buelens O, Lade S, et al. The importance of differentiating between mycosis fungoides with CD30-positive large cell transformation and mycosis fungoides with coexistent primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol 2021;84:185–7.
Kadin ME, Hughey LC, Wood GS. Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium. J Am Acad Dermatol 2014;70:374–6.
Kari LJ, Kadin ME, Hsi ED, Sluzevich JC, Ketterling RP, Knudson RA, et al. Chromosomal rearrangements of 6p25.3 define a new subtype of lymphomatoid papulosis. Am J Surg Pathol 2013;37:1173–81.
Kempf W, Kerl K, Mitteldorf C. Cutaneous CD30-positive T-cell lymphoproliferative disorders-clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg 2018;37:24–9.
Kempf W, Pfaltz K, Vermeer MH, Cozzio A, Ortiz-Romero PL, Bagot M, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011;118:4024–35.
Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010;363:2424–33.
Lemza LS, Gratzingier D. Nodal involvement by CD30+ cutaneous lymphoproliferative disorders and its challenging differentiation from classical Hodgkin lymphoma. Arch Pathol Lab Med 2018;142:139–42.
Maurus K, Appenzeller S, Roth S, Brändle S, Kneitz H, Goebeler M, et al. Recurrent oncogenic JAK and STAT alterations in cutaneous CD30-positive lymphoproliferative disorders. J Invest Dermatol 2020;140:2023–31.e1.
McGirt LY, Jia P, Baerenwald DA, Duszynski RJ, Dahlman KB, Zic JA, et al. Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood 2015;126:508–19.
Melchers RC, Willemze R, Bekkenk MW, de Haas ERM, Horvath B, van Rossum MM, et al. Frequency and prognosis of associated malignancies in 504 patients with lymphomatoid papulosis. J Eur Acad Dermatol Venereol 2020a;34:260–6.
Melchers RC, Willemze R, van de Loo M, van Doorn R, Jansen PM, Cleven AHG, et al. Clinical, histologic, and molecular characteristics of anaplastic lymphoma kinase-positive primary cutaneous anaplastic large cell lymphoma. Am J Surg Pathol 2020b;44:776–81.
Melchers RC, Willemze R, Vermaat JSP, Jansen PM, Daniels LA, Putter H, et al. Outcomes of rare patients with a primary cutaneous CD30+ lymphoproliferative disorder developing extracutaneous disease. Blood 2020c;135:769–73.
Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) [published correction appears in Blood 2008;111:4830]. Blood 2007;110:1713–22.
Palomero T, Couronné L, Khiabian H, Kim MY, Ambesi-Impombo A, Perez-Garcia A, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 2014;46:166–70.
Park DJ, Kwon A, Cho BS, Kim HJ, Hwang KA, Kim M, et al. Characteristics of DNMT3A mutations in acute myeloid leukemia. Blood Res 2020;55:17–26.
Pham-Ledard A, Prochazkova-Carlotti M, Laharanne E, Verger B, Jouary T, Beylot-Bary M, et al. IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases. J Invest Dermatol 2010;130:816–25.
Prasad A, Rabionet R, Espinet B, Zapata L, Puiugros A, Melero C, et al. Identification of gene mutations and fusion genes in patients with Sézary syndrome. J Invest Dermatol 2016;136:1490–9.
Stowman AM, Hsia LL, Kanner WA, Mahadevan MS, Bullock GC, Patterson JW. Multiple cutaneous lymphoproliferative disorders showing a
Tensen CP. PLCG1 gene mutations in cutaneous T-cell lymphomas revisited. J Invest Dermatol 2015;135:2153–4.

Thorvaldsdóttir H, Robinson JT, Mesirov JP. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 2013;14:178–92.

Ungewickell A, Bhaduri A, Rios E, Reuter J, Lee CS, Mah A, et al. Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2. Nat Genet 2015;47:1056–60.

van Dongen JJ, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender FL, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17:2257–317.

Vaqué JP, Gómez-López G, Monsálvez V, Varela I, Martínez N, Pérez C, et al. PLCG1 mutations in cutaneous T-cell lymphomas. Blood 2014;123:2034–43.

Velusamy T, Kiel MJ, Sahasrabuddhe AA, Rolland D, Dixon CA, Bailey NG, et al. A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. Blood 2014;124:3768–71.

Vergier B, de Muret A, Bélyot-Barry M, Vaillant L, Ekouevi D, Chene G, et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneous Lymphomas. Blood 2000;95:2212–8.

Wada DA, Law ME, Hsi ED, Dicaudo DJ, Ma L, Lim MS, et al. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol 2011;24:596–605.

Wang L, Ni X, Covington KR, Yang BY, Shiu J, Zhang X, et al. Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes. Nat Genet 2015;47:1426–34.

Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas [published correction appears in Blood 2019;134:1112]. Blood 2019;133:1703–14.

Willemze R, Meijer CJ. Primary cutaneous CD30-positive lymphoproliferative disorders. Hematol Oncol Clin North Am 2003;17:1319–viii.

Woollard WJ, Pullabhatla V, Lorenz A, Patel VM, Butler RM, Bayega A, et al. Candidate driver genes involved in genome maintenance and DNA repair in Sézary syndrome. Blood 2016;127:3387–97.

Xerri L, Adélaïde J, Avenin M, Guille A, Taix S, Bonnet N, et al. Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome-wide clonal evolution. Histopathology 2019;74:654–62.

Zackheim HS, Jones C, Leboit PE, Kashani-Sabet M, McCalmont TH, Zehnder J. Lymphomatoid papulosis associated with mycosis fungoides: a study of 21 patients including analyses for clonality [published correction appears in J Am Acad Dermatol 2004;50:202]. J Am Acad Dermatol 2003;49:620–3.